Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 2087-2093

  Voigt, W ^a   Bulankin, A ^a   Muller T ^a   Schoeber, C ^a   Grothey, A ^a   Hoang Vu, C ^a   Schmoll, H J ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE;

ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOSTASIS; DNA SYNTHESIS INHIBITION; DRUG ANTAGONISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THYROID CARCINOMA;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CISPLATIN; DEOXYCYTIDINE; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG SYNERGISM; HUMANS; THYROID NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034026355     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Demeter, J. G., De Jong, S. A., Lawrence, A. M., and Paloyan, E. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery, 110: 956-961, 1991.
2. Tennvall, J.. Lundell, G., Hallquist, A., Wahlberg, P., Wallin, G., and Tibblin, S. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer (Phila.), 74: 1348-1354, 1994.
3. Kim, J. H., and Leeper, R. D. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer (Phila.), 60: 2372-2375, 1987.
4. Schlumberger, M., Parmentier, C., Delisle, M. J., Couette, J. E., Droz, J. P., and Sarrazin, D. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer (Phila.), 67: 564-566, 1991.
5. Steward, W. P. Combination studies with gemcitabine in the treatment of non-small-cell lung cancer. Br. J. Cancer, 78(Suppl. 3): 15-19, 1998.
6. Carmichael, J. The role of gemcitabine in the treatment of other tumours. Br. J. Cancer, 78(Suppl. 3): 21-25, 1998.
7. Storniolo, A. M., Allerheiligen, S. R., and Pearce, H. L. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin. Oncol., 24: S72-S77, 1997.
8. Peters, G. J., Bergman, A. M., Ruiz van Haperen, V. W., Veerman, G., Kuiper, C. M., and Braakhuis, B. J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol., 22: 72-79, 1995.
9. Plunkett, W., Huang, P., Xu, Y. Z., Heinemann, V., Grunewald, R., and Gandhi, V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol., 22: 3-10, 1995.
10. Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991.
11. Ruiz van Haperen, V. W., Veerman, G., Vermorken, J. B., and Peters, G. J. 2′,2′-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. 46: 762-766, 1993.
12. Heinemann, V., Schulz, L., Issels, R. D., and Plunkett, W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin. Oncol., 22: 11-18, 1995.
13. Perez, R. P. Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer, 34: 1535-1542, 1998.
14. Eastman, A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther., 34: 155-166, 1987.
15. Fink, D. Z. H., Nebel, S., Norris, S., Aebi, S., Lin, T-P., Nehme, A., Christen, R. D., Haas, M., MacLeod, C. L., and Howell, S. B. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res., 57: 1841-1845, 1997.
16. van Moorsel, C. J., Veerman, G., Bergman, A. M., Guechev, A., Vermorken, J. B., Postmus, P. E., and Peters, G. J. Combination chemotherapy studies with gemcitabine. Semin. Oncol., 24: S717-S723, 1997.
17. Peters, G. J., Ruiz van Haperen, V. W., Bergman, A. M., Veerman, G., Smitskamp Wilms, E., van Moorsel, C. J., Kuiper, C. M., and Braakhuis, B. J. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin. Oncol., 23: 16-24, 1996.
18. Braakhuis, B. J., Ruiz van Haperen, V. W., Welters, M. J., and Peters, G. J. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur. J. Cancer, 31a: 2335-2340, 1995.
19. Bergman, A. M., Ruiz van Haperen, V. W., Veerman, G., Kuiper, C. M., and Peters, G. J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res., 2: 521-530, 1996.
20. Tsai, C. M., Chang, K. T., Chen, J. Y., Chen, Y. M., Chen, M. H., and Perng, R. P. Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu. Cancer Res., 56: 794-801, 1996.
21. Aust, G., Eichler, W., Laue, S., Lehmann, I., Heldin, N. E., Lotz, O., Scherbaum, W. A., Dralle, H., and Hoang Vu, C. CD97: a dedifferendation marker in human thyroid carcinomas. Cancer Res., 57: 1798-1806, 1997.
22. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
23. Ohe, Y., Nakagawa, K., Fujiwara, Y., Sasaki, Y., Minato, K., Bungo, M., Niimi, S., Horichi, N., Fukuda, M., and Saijo, N. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res., 49: 4098-4102, 1989.
24. Berenbaum, M. C. What is synergy? (published erratum appears in Pharmacol. Rev., 41: 422, 1990). Pharmacol. Rev., 41: 93-141, 1989.
25. van Moorsel, C. J., Pinedo, H. M., Veerman, G., Bergman, A. M., Kuiper, C. M., Vermorken, J. B., van der Vijgh, W. J., and Peters, G. J. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br. J. Cancer, 80: 981-990, 1999.
26. Abbruzzese, J. L., Grunewald, R., Weeks, E. A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Tarassoff, P., Satterlee, W., Raber, M. N., and Plunle, H. W. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol., 9: 491-498, 1991.
27. Fukuda, M., Ohe, Y., Kanzawa, F., Oka, M., Hara, K., and Saijo, N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res., 15: 393-398, 1995.
28. Horiuchi, N., Nakagawa, K., Sasaki, Y., Minato, K., Fujiwara, Y., Nezu, K., Ohe, Y., and Saijo, N. In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay. Cancer Chemother. Pharmacol., 22: 246-250, 1988.
29. van Moorsel, C. J. A., Veerman, H. M. P. G., Vermorken, J. B., Postmus, P. E., and Peters, G. J. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur. J. Cancer, 35: 808-814, 1999.
30. Crino, L., Scagliotti, G., Marangolo, M.. Figoli, F., Clerici, M., De Marinis, F., Salvati, F., Cruciani, G., Dogliotti, L., Pucci, F., Paccagnella, A., Adamo, V., Altavilla, G., Incoronato, P., Trippetti, M., Mosconi, A. M., Santucci, A., Sorbolini, S., Oliva, C., and Tonato, M. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol., 15: 297-303, 1997.
31. Bunch, R. T., and Eastman, A. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ., 8: 779-788, 1997.
32. Lin, X. H. S. B. Effect of loss of DNA mismatch repair on the development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin. Mol. Pharmacol., 56: 390-395, 1999.